+22%

est. 2Y upside i

Healthcare

Rank

#2981

Sector

Biotechnology

Est. Liquidity

~0Y

Data Quality

Data: High

Insmed presents a moderate upside opportunity for a job seeker over a 2-year horizon, driven by its impressive revenue growth (67% YoY) and the strong commercial performance of BRINSUPRI, projected to reach at least $1 billion in 2026.

Last updated: March 10, 2026

Bull (35%)+75%

Successful Phase 3 ENCORE trial for ARIKAYCE and strong global launch of BRINSUPRI, exceeding $1.5B in combined revenue by 2027, coupled with positive TPIP pipeline data, drives a re-rating to a $52B+ valuation as profitability becomes visible.

Base (40%)+15%

ARIKAYCE maintains steady growth, and BRINSUPRI achieves its $1B+ revenue target for 2026, with some pipeline progress. Valuation remains elevated but justified by continued revenue expansion to ~$1.8B by 2027, leading to a modest increase to a $34B+ valuation.

Bear (25%)-40%

Pipeline setbacks, particularly negative ENCORE or CEDAR trial results, or slower-than-expected BRINSUPRI uptake due to competitive pressures, lead to a significant valuation correction. Revenue growth stalls, and the company's high P/S ratio contracts to industry averages, resulting in a valuation closer to $18B.

Est. time to liquidity~0.0 years

Preference Stack Risk

low

As a publicly traded company, employees holding common stock or options are not subject to liquidation preferences typically associated with preferred shares in private companies.

Dilution Risk

moderate

Future capital raises or equity-based compensation plans could lead to moderate dilution for existing shareholders.

Secondary Liquidity

active

As a publicly traded company on NASDAQ, Insmed shares are actively traded on the open market, providing immediate liquidity.

Other — 8 roles

View all 8 open roles at Insmed →

Last updated: February 17, 2026

Questions to Ask at the Interview

Strategic questions based on Insmed's data — designed to show you've done your homework.

  • 1

    “Given the high P/S ratio compared to industry peers, how does Insmed plan to demonstrate sustained value creation to justify its current valuation over the next 2-3 years, particularly as BRINSUPRI scales?”

  • 2

    “With several key pipeline readouts expected in 2026 for ARIKAYCE (ENCORE), BRINSUPRI (CEDAR), and TPIP, how is Insmed managing the associated clinical and regulatory risks to ensure continued growth?”

  • 3

    “Considering the significant R&D and SG&A expenses contributing to unprofitability, what is the company's strategic roadmap to achieve profitability and positive free cash flow within the next 2-3 years?”

Community

Valuation Sentiment

Our model estimates +22% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.